

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 5, 2023

**APOLLO MEDICAL HOLDINGS, INC.**  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-37392  
(Commission  
File Number)

95-4472349  
(I.R.S. Employer  
Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801  
(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288  
Registrant's Telephone Number, Including Area Code

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02 Results of Operations and Financial Condition.**

On May 8, 2023, Apollo Medical Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by this reference.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer. Mr. Basho previously served as interim Chief Financial Officer. He will continue to serve as Chief Strategy Officer.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release of Apollo Medical Holdings, Inc. Regarding its Financial Results for the Quarter Ended March 31, 2023, dated May 8, 2023.</a>
99.2	<a href="#">Supplemental Data of Apollo Medical Holdings, Inc., dated May 8, 2023.</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APOLLO MEDICAL HOLDINGS, INC.**

Date: May 8, 2023

By: /s/ Thomas S. Lam  
Name: Thomas S. Lam, M.D., M.P.H.  
Title: Co-Chief Executive Officer and President



**Apollo Medical Holdings, Inc. Reports First Quarter 2023 Results**  
**Company to Host Conference Call on Monday, May 8, 2023, at 2:30 p.m. PT/5:30 p.m. ET**

ALHAMBRA, Calif., May 8, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the first quarter ended March 31, 2023.

**Financial Highlights for First Quarter Ended March 31, 2023:**

- Total revenue of \$337.2 million, up 28% from \$263.3 million for the prior-year quarter
- Net income attributable to ApolloMed of \$14.6 million, up 3% from \$14.3 million for the prior-year quarter
- Earnings per share - diluted ("EPS - diluted") of \$0.31, compared to \$0.31 per share for the prior-year quarter
- Adjusted EBITDA of \$29.8 million, compared to \$34.4 million for the prior-year quarter
- Beginning with the first quarter ended March 31, 2023, the Company is reporting its financial results based on the following three business segments, in an effort to provide greater insight into the performance of its different lines of business:
  1. Care Enablement (integrated, end-to-end clinical and administrative platform comprised of technology, analytics, and management services, which enable payers and providers in the delivery of high-quality, value-based care);
  2. Care Partners (partnering with high-performing providers in reducing total cost of care and participating in risk-bearing and performance-based arrangements via our consolidated risk-bearing entities, including independent physician associations ("IPAs"), health plan, and accountable care organization ("ACO")); and
  3. Care Delivery (clinical operations, including primary care, multi-specialty, and ancillary services).

**Recent Operating Highlights:**

- On May 1, 2023, the Company completed the previously announced acquisition of 100% of the fully diluted capitalization of For Your Benefit, Inc. ("FYB"). The Company has also received approval of the change in control of FYB's license as a full-service Restricted Knox-Keene licensed health plan from the California Department of Managed Health Care. With this approval, ApolloMed is now able to assume full financial responsibility, including both professional and institutional risk, in California for the medical costs of its members/enrollees through plan-to-plan contracts with licensed health plans.
- On May 5, 2023, the Company's Board of Directors approved the appointment of Chan Basho as Chief Financial Officer. Mr. Basho will remain in his role as Chief Strategy Officer and will continue to oversee the finance, operations, strategy and corporate development teams.

**Management Commentary:**

Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "We began 2023 on a strong note, achieving 28% growth on the top line primarily due to organic growth in our Care Partners segment, and maintaining steady profitability even as we continue to invest in people and infrastructure in our Care Enablement segment and continue to expand our high-quality clinical footprint in our Care Delivery segment. We continue to execute on our core operational goals, especially in growing our membership in core and new geographic regions and in taking additional financial responsibility for care delivery in our risk-bearing entities. On the latter, we recently received regulatory approval for the change in control of a full-service Restricted Knox-Keene licensed health plan, which will allow us to take global risk for the professional and institutional costs of members in the plan. This is a significant opportunity for us to deploy our care coordination and management capabilities more effectively and enhances our demonstrated ability to decrease total cost of care while improving on quality and patient outcomes, which we expect will drive both revenue and EBITDA growth over the next several years."

---

Mr. Sim continued, “Given our strong start to the year and ongoing execution across our business, we are pleased to be reiterating our previously provided guidance for full-year 2023. I believe that our innovative, technology-forward healthcare delivery platform, consisting of the rapidly-growing risk-bearing partnerships we have developed in conjunction with our growing clinical delivery footprint, all powered by our end-to-end care enablement suite, positions us well in our mission to accelerate the transformation of our healthcare system into one that is seamlessly coordinated, high quality, and accessible by all.”

**GAAP Financial Review for the First Quarter Ended March 31, 2023:**

- Total revenue of \$337.2 million for the quarter ended March 31, 2023, an increase of 28%, compared to \$263.3 million for the quarter ended March 31, 2022.
- Capitation revenue, net, of \$300.2 million for the quarter ended March 31, 2023, an increase of 35%, compared to \$222.1 million for the quarter ended March 31, 2022. Capitation revenue represented 89% of total revenue for the quarter ended March 31, 2023.
- Net income of \$14.3 million for the quarter ended March 31, 2023, an increase of 19%, compared to \$12.1 million for the quarter ended March 31, 2022.
- Net income attributable to ApolloMed of \$14.6 million for the quarter ended March 31, 2023, compared to \$14.3 million for the quarter ended March 31, 2022.
- EPS - diluted of \$0.31 per share for the quarter ended March 31, 2023, compared to \$0.31 per share for the quarter ended March 31, 2022.

**Segment Results for the First Quarter Ended March 31, 2023:**

	Three months ended March 31, 2023						
	Care Enablement	Care Partners	Care Delivery	Other	Intersegment Elimination	Corporate Costs	Consolidated Total
Total revenues	\$ 30,566	\$ 314,653	\$ 25,383	\$ 240	\$ (33,598)	\$ —	\$ 337,244
Cost of services	15,621	286,078	21,363	63	(33,728)	—	289,397
General and administrative <sup>(1)</sup>	9,199	6,254	4,986	660	(1,034)	5,409	25,474
Total expenses	24,820	292,332	26,349	723	(34,762)	5,409	314,871
Income (loss) from operations	\$ 5,746	\$ 22,321	\$ (966)	\$ (483)	\$ 1,164 <sup>(2)</sup>	\$ (5,409)	\$ 22,373

<sup>(1)</sup> Balance includes general and administrative expenses and depreciation and amortization.

<sup>(2)</sup> Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.

Care Enablement reported total revenues of \$30.6 million for the quarter ended March 31, 2023, an increase of 4.0%, compared to \$29.4 million for the quarter ended March 31, 2022. Segment operating income was \$5.7 million, compared to \$11.3 million in the prior-year period. This decrease was primarily a result of a \$2.1 million increase in cost of services as well as \$4.7 million increase in G&A expense related to increased headcount to support the Company’s operational growth.

Care Partners reported total revenue of \$314.7 million for the quarter ended March 31, 2023, an increase of 30.4%, compared to \$241.3 million for the quarter ended March 31, 2022, which was primarily driven by organic membership growth in ApolloMed’s consolidated risk-bearing entities and a more favorable payer mix. Segment operating income was \$22.3 million, an increase of 28.2% from \$17.4 million in the prior-year period.

Care Delivery reported total revenues of \$25.4 million for the quarter ended March 31, 2023, an increase of 24.9%, compared to \$20.3 million for the quarter ended March 31, 2022, which was primarily driven by increased volume in patient visits at our primary, multi-specialty, and ancillary care delivery entities. Segment operating loss was \$1.0 million, compared to operating income of \$1.1 million in the prior-year period. The loss was primarily a result of the Company's ongoing investment in expanding its care delivery footprint in Nevada and Texas.

**Non-GAAP Measures for the First Quarter Ended March 31, 2023:**

- EBITDA of \$24.0 million for the quarter ended March 31, 2023, compared to \$23.7 million for the quarter ended March 31, 2022.
- Adjusted EBITDA of \$29.8 million for the quarter ended March 31, 2023, compared to \$34.4 million for the quarter ended March 31, 2022. The decrease was primarily due to a \$6.5 million reduction in APC excluded assets costs, which was related to significantly lower non-cash unrealized losses in fair value of a payer partner's shares held as marketable securities and other investments of \$3.0 million, compared to \$10.6 million in unrealized losses for the quarter ended March 31, 2022.

**Balance Sheet Highlights:**

As of March 31, 2023, ApolloMed's cash and cash equivalents and investments in marketable securities were \$278.7 million, working capital was \$292.7 million, and total stockholders' equity was \$563.2 million; compared to cash and cash equivalents and investments in marketable securities of \$293.6 million, working capital of \$287.8 million and total stockholders' equity of \$555.0 million, respectively, as of December 31, 2022.

**Update on Share Repurchase Program**

In December 2022, ApolloMed's Board of Directors approved a share repurchase plan authorizing the Company to repurchase up to \$50.0 million of its shares of common stock on the open market and through privately negotiated transactions. The Company repurchased \$9.5 million, or approximately 270,000 shares, during the quarter ended March 31, 2023. This share repurchase plan does not have an expiration date. The Board may suspend or discontinue the repurchase program at any time. This repurchase program does not obligate the Company to make additional repurchases at any specific time or in any specific situation.

For more details on ApolloMed's financial results for the quarter ended March 31, 2023, please refer to ApolloMed's Quarterly Report on Form 10-Q to be filed with the U.S. Securities Exchange Commission ("SEC"), which is accessible at [www.sec.gov](http://www.sec.gov).

**Guidance:**

ApolloMed is reiterating the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and EPS - diluted, based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.

(\$ in millions)

	2023 Guidance Range	
	Low	High
Total revenue	\$ 1,300.0	\$ 1,500.0
Net income	\$ 49.5	\$ 71.5
EBITDA	\$ 89.5	\$ 129.5
Adjusted EBITDA	\$ 120.0	\$ 160.0
EPS – diluted	\$ 0.95	\$ 1.20

See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

**Conference Call and Webcast Information:**

ApolloMed will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Monday, May 8, 2023), during which management will discuss the results of the first quarter ended March 31, 2023. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

U.S. & Canada (Toll-Free): +1 (877) 858-9810  
International (Toll): +1 (201) 689-8517

The conference call can also be accessed via webcast at: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=y00KycVd>.

An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website (<https://www.apollomed.net/investors/news-events/ir-calendar>) after issuance of the earnings release and will be furnished as an exhibit to ApolloMed’s current report on Form 8-K to be filed with the SEC, accessible at [www.sec.gov](http://www.sec.gov).

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

**Note About Consolidated Entities**

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company’s consolidated statements of income.

**Note About Stockholders’ Equity, Certain Treasury Stock and Earnings Per Share**

As of the date of this press release, 140,954 holdback shares have not been issued to certain former shareholders of the Company’s subsidiary, Network Medical Management, Inc. (“NMM”), who were NMM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed’s common stock and warrants as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among ApolloMed, NMM, Apollo Acquisition Corp. (“Merger Subsidiary”) and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into NMM, with NMM as the surviving corporation. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company’s consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered profunctory and ApolloMed is legally obligated to issue these shares in connection with the merger.

Shares of ApolloMed’s common stock owned by Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California (“APC”), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company’s consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company’s earnings per share.

**About Apollo Medical Holdings, Inc.**

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver outcomes-based medical care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed’s subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit [www.apollomed.net](http://www.apollomed.net).

---

**Forward-Looking Statements**

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending December 31, 2023, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, and successful implementation of strategic growth plans, acquisition strategy, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and any subsequent quarterly reports on Form 10-Q.*

**FOR MORE INFORMATION, PLEASE CONTACT:**

Investor Relations  
(626) 943-6491  
[investors@apollomed.net](mailto:investors@apollomed.net)

Carolyne Sohn, The Equity Group  
(408) 538-4577  
[csohn@equityny.com](mailto:csohn@equityny.com)

---



**APOLLO MEDICAL HOLDINGS, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

	<b>March 31, 2023</b>	<b>December 31, 2022</b>
	(Unaudited)	
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 274,613	\$ 288,027
Investments in marketable securities	4,114	5,567
Receivables, net	79,003	52,629
Receivables, net – related parties	74,877	65,147
Income taxes receivable	9	4,015
Other receivables	1,929	1,834
Prepaid expenses and other current assets	22,170	14,798
Loans receivable	973	996
Loan receivable – related party	—	2,125
<b>Total current assets</b>	<b>457,688</b>	<b>435,138</b>
<b>Non-current assets</b>		
Land, property, and equipment, net	113,361	108,536
Intangible assets, net	77,675	76,861
Goodwill	276,028	275,675
Investments in other entities – equity method	43,108	40,299
Investments in privately held entities	896	896
Operating lease right-of-use assets	18,431	20,444
Other assets	5,441	6,056
<b>Total non-current assets</b>	<b>534,940</b>	<b>528,767</b>
<b>Total assets<sup>(1)</sup></b>	<b>\$ 992,628</b>	<b>\$ 963,905</b>
<b>Liabilities, mezzanine equity and equity</b>		
<b>Current liabilities</b>		
Accounts payable and accrued expenses	\$ 49,486	\$ 49,562
Fiduciary accounts payable	8,976	8,065
Medical liabilities	101,394	84,253
Dividend payable	664	664
Finance lease liabilities	579	594
Operating lease liabilities	3,234	3,572

	March 31, 2023	December 31, 2022
Current portion of long-term debt	621	619
Total current liabilities	164,954	147,329
<b>Non-current liabilities</b>		
Deferred tax liability	3,695	3,042
Finance lease liabilities, net of current portion	1,136	1,275
Operating lease liabilities, net of current portion	18,164	19,915
Long-term debt, net of current portion and deferred financing costs	204,944	203,389
Other long-term liabilities	21,806	20,260
Total non-current liabilities	249,745	247,881
<b>Total liabilities<sup>(1)</sup></b>	414,699	395,210
<b>Mezzanine equity</b>		
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation	14,729	13,682
<b>Stockholders' equity</b>		
Series A Preferred stock, par value \$0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding	—	—
Series B Preferred stock, par value \$0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding	—	—
Common stock, \$0.001 par value per share; 100,000,000 shares authorized, 46,488,443 and 46,575,699 shares issued and outstanding, excluding 10,569,340 and 10,299,259 treasury shares, at March 31, 2023, and December 31, 2022, respectively	47	47
Additional paid-in capital	352,697	360,097
Retained earnings	207,300	192,678
Total stockholders' equity	560,044	552,822
Non-controlling interest	3,156	2,191
Total equity	563,200	555,013
<b>Total liabilities, mezzanine equity and equity</b>	<u>\$ 992,628</u>	<u>\$ 963,905</u>

<sup>(1)</sup> The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling \$519.9 million and \$505.8 million as of March 31, 2023 and December 31, 2022, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of \$131.8 million and \$129.7 million as of March 31, 2023 and December 31, 2022, respectively. The VIE balances do not include \$375.6 million of investment in affiliates and \$34.0 million of amounts due from affiliates as of March 31, 2023 and \$304.8 million of investment in affiliates and \$30.3 million of amounts due from affiliates as of December 31, 2022 as these are eliminated upon consolidation and not presented within the consolidated balance sheets.

**APOLLO MEDICAL HOLDINGS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)  
(UNAUDITED)

	<b>Three Months Ended March 31,</b>	
	<b>2023</b>	<b>2022</b>
<b>Revenue</b>		
Capitation, net	\$ 300,204	\$ 222,060
Risk pool settlements and incentives	13,462	18,075
Management fee income	9,896	10,473
Fee-for-service, net	12,062	11,095
Other income	1,620	1,555
<b>Total revenue</b>	<b>337,244</b>	<b>263,258</b>
<b>Operating expenses</b>		
Cost of services, excluding depreciation and amortization	289,397	220,730
General and administrative expenses	21,182	11,943
Depreciation and amortization	4,292	4,374
<b>Total expenses</b>	<b>314,871</b>	<b>237,047</b>
<b>Income from operations</b>	<b>22,373</b>	<b>26,211</b>
<b>Other (expense) income</b>		
Income from equity method investments	2,484	1,433
Interest expense	(3,269)	(1,073)
Interest income	3,009	46
Unrealized loss on investments	(6,392)	(8,962)
Other income	1,204	613
<b>Total other expense, net</b>	<b>(2,964)</b>	<b>(7,943)</b>
<b>Income before provision for income taxes</b>	<b>19,409</b>	<b>18,268</b>
Provision for income taxes	5,102	6,195
<b>Net income</b>	<b>14,307</b>	<b>12,073</b>
Net loss attributable to non-controlling interest	(315)	(2,191)
<b>Net income attributable to Apollo Medical Holdings, Inc.</b>	<b>\$ 14,622</b>	<b>\$ 14,264</b>
<b>Earnings per share – basic</b>	<b>\$ 0.31</b>	<b>\$ 0.32</b>
<b>Earnings per share – diluted</b>	<b>\$ 0.31</b>	<b>\$ 0.31</b>

**Reconciliation of Net Income to EBITDA and Adjusted EBITDA**

<i>(in thousands)</i>	Three Months Ended March 31,	
	2023	2022
Net income	\$ 14,307	\$ 12,073
Interest expense	3,269	1,073
Interest income	(3,009)	(46)
Provision for income taxes	5,102	6,195
Depreciation and amortization	4,292	4,374
<b>EBITDA</b>	<b>23,961</b>	<b>23,669</b>
Income from equity method investments	(249)	(148)
Other, net	1,402 <sup>(1)</sup>	—
Stock-based compensation	3,445	3,055
APC excluded assets costs	1,266	7,784
<b>Adjusted EBITDA</b>	<b>\$ 29,825</b>	<b>\$ 34,360 <sup>(2)</sup></b>

<sup>(1)</sup> Other, net for the three months ended March 31, 2023 relates to changes in the fair value of our financing obligation to purchase the remaining equity interest in one of our investments.

<sup>(2)</sup> Adjusted EBITDA under the historical method for the three months ended March 31, 2022 was \$38.2 million. See “Use of Non-GAAP Financial Measures” below for additional information on change of methodology.

**Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA**

<i>(in thousands)</i>	2023 Guidance Range	
	Low	High
Net income	\$ 49,500	\$ 71,500
Interest expense	1,000	1,000
Provision for income taxes	23,000	38,000
Depreciation and amortization	16,000	19,000
<b>EBITDA</b>	<b>89,500</b>	<b>129,500</b>
Loss (income) from equity method investments	(750)	(750)
Other, net	3,250	3,250
Stock-based compensation	16,000	16,000
APC excluded assets costs	12,000	12,000
<b>Adjusted EBITDA</b>	<b>\$ 120,000</b>	<b>\$ 160,000</b>

### **Use of Non-GAAP Financial Measures**

This press release contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.



# Apollo Medical Holdings

(NASDAQ: AMEH)

First Quarter 2023 Earnings Call Supplement  
May 8, 2023

Powered by Technology.

Built by Doctors.

For Patients.



# Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "plan," "envision," "intend," "continue," "target," "seek," "will," "would," and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the U.S. Securities and Exchange Commission (the "SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent Quarterly Reports on Form 10-Q.

Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.

# Company Overview

**ApolloMed** is a technology-powered, value-based care healthcare platform that enables the delivery of high-quality, coordinated, efficient, and accessible care for all through the following business segments:

**Care Enablement** delivers an integrated clinical and administrative platform to enable payers and providers in the delivery of high quality, value based care.

**Care Partners** enables aligned providers to participate in high-performance risk-bearing organizations.

**Care Delivery** provides patient centric clinical operations, including primary care, multi-specialty, and ancillary services.

25+

years in operation

1.3M

managed lives

15\*

managed IPAs and groups

12,000+

contracted physicians



IPA: independent physician association \*As of 3/31/2023

## ApolloMed At-A-Glance

Ticker NASDAQ: AMEH

Headquarters Alhambra, California

Recent Stock Price  
(as of 5/4/2023) \$34.15

Market Cap  
(as of 5/4/2023) \$2.0 billion

Common Shares  
Outstanding\*  
(as of 5/2/2023) 57.5 million

Book Value Per  
Common Share \$9.79

TTM Revenues \$1.22 billion

\*Includes 10.6 million in treasury shares  
Information as of 3/31/2023 unless otherwise noted



# Highlights

## Strong Q1 2023 financial results

Revenue	\$337.2M	↑ 28%
Net income attr. to AMEH	\$14.6M	↑ 3%
EPS - diluted	\$0.31	
Adj. EBITDA*	\$29.8M	

## Operational updates


Received DHMC approval for the change of control for FYB's Restricted Knox-Keene license to ApolloMed

Appointed Chan Basho as Chief Financial Officer, maintaining the role of Chief Strategy Officer



\*See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" slides for more information. Please note that beginning the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude addbacks related to provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

# Historical Financial Profile



(1) See "Use of Non-GAAP Financial Measures" slide for more information.

# Summary of Selected Financial Results

	Three Months Ended March 31,	
<i>\$ in 000s except per share data</i>	2023	2022
<b>Revenue</b>		
Capitation, net	\$ 300,204	\$ 222,060
Risk pool settlements and incentives	13,462	18,075
Management fee income	9,896	10,473
Fee-for-service, net	12,062	11,095
Other income	1,620	1,555
<b>Total revenue</b>	<b>337,244</b>	<b>263,258</b>
Total expenses	314,871	237,047
<b>Income from operations</b>	<b>22,373</b>	<b>26,211</b>
<b>Net income</b>	<b>14,307</b>	<b>12,073</b>
Net loss attributable to noncontrolling interests	(315)	(2,191)
<b>Net income attributable to ApolloMed</b>	<b>\$ 14,622</b>	<b>\$ 14,264</b>
<b>Earnings per share - diluted</b>	<b>\$ 0.31</b>	<b>\$ 0.31</b>

# Segment Results

For the three months ended March 31, 2023

\$ in 000s	Care Enablement	Care Partners	Care Delivery	Other	Intersegment Elimination	Corporate Costs	Consolidated Total
<b>Total revenues</b>	\$ 30,566	314,653	25,383	240	(33,598)	-	337,244
Cost of services	15,621	286,078	21,363	63	(33,728)	-	289,397
General and administrative expenses <sup>(1)</sup>	9,199	6,254	4,986	660	(1,034)	5,409	25,474
<b>Total expenses</b>	24,820	292,332	26,349	723	(34,762)	5,409	314,871
<b>Income (loss) from operations</b>	\$ 5,746	22,321	(966)	(483)	1,164 <sup>(2)</sup>	(5,409)	22,373

For the three months ended March 31, 2022

\$ in 000s	Care Enablement	Care Partners	Care Delivery	Other	Intersegment Elimination	Corporate Costs	Consolidated Total
<b>Total revenues</b>	\$ 29,390	241,293	20,326	89	(27,840)	-	263,258
Cost of services	13,517	218,673	16,192	45	(27,697)	-	220,730
General and administrative expenses <sup>(1)</sup>	4,529	5,213	3,043	476	(619)	3,675	16,317
<b>Total expenses</b>	18,046	223,886	19,235	521	(28,316)	3,675	237,047
<b>Income (loss) from operations</b>	\$ 11,344	17,407	1,091	(432)	476 <sup>(2)</sup>	(3,675)	26,211



<sup>(1)</sup> Balance includes general and administrative expenses and depreciation and amortization.

<sup>(2)</sup> Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income, which is not presented in the table.

# Revenue Breakdown

## Revenue by Line of Business



## Business Mix By Payer Type



# Balance Sheet Highlights

---

<i>\$ in millions</i>	3/31/2023	12/31/2022	\$ Change	% Change
Cash and cash equivalents and investments in marketable securities	\$278.7	\$293.6	(\$14.9)	↓ 5%
Working capital	\$292.7	\$287.8	\$4.9	↑ 2%
Total stockholders' equity	\$563.2	\$555.0	\$8.2	↑ 2%

# 2023 Guidance

*\$ in millions, except for per share information*

## Actual YE 2022 Results    2023 Guidance Range

Total Revenue	\$1,144.2	\$1,300.0-\$1,500.0
Net Income <sup>(1)</sup>	\$50.5	\$49.5-\$71.5
EBITDA <sup>(1,2)</sup>	\$110.1	\$89.5-\$129.5
Adjusted EBITDA <sup>(2)</sup>	\$140.0	\$120.0-\$160.0
EPS - Diluted	\$1.08	\$0.95-\$1.20

(1) Net income and EBITDA forecast includes the impact of APC excluded assets, which assume no change in value.

(2) See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" on slide 2.

# Reconciliation of Net Income to EBITDA and Adjusted EBITDA

(\$ in millions)	Three months ended March 31,	
	2023	2022
Net income	\$ 14.3	\$ 12.1
Interest expense	3.3	1.1
Interest income	(3.0)	(0.1)
Provision for income taxes	5.1	6.2
Depreciation and amortization	4.3	4.4
<b>EBITDA<sup>(1)</sup></b>	<b>\$ 24.0</b>	<b>\$ 23.7</b>
Income from equity method investments	\$ (0.2)	\$ (0.1)
Other, net	1.4 <sup>(2)</sup>	-
Stock-based compensation	3.4	3.1
APC excluded assets costs	1.3	7.8
<b>Adjusted EBITDA<sup>(1)</sup></b>	<b>\$ 29.8</b>	<b>\$ 34.4<sup>(3)</sup></b>

(1) See "Use of Non-GAAP Financial Measures" slide for more information.

(2) Other, net for the three months ended March 31, 2023, relates to changes in the fair value of the Company's financing obligations to purchase the remaining equity interest in one of its investments.

(3) Adjusted EBITDA under the historical method for the three months ended March 31, 2022, was \$38.2 million. See "Use of Non-GAAP Financial Measures" slide for additional information on change of methodology.



# Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA

(\$ in millions)	Year Ending December 31, 2023	
	Low	High
Net income	\$ 49.5	\$ 71.5
Interest expense	1.0	1.0
Provision for income taxes	23.0	38.0
Depreciation and amortization	16.0	19.0
<b>EBITDA<sup>(1)</sup></b>	<b>\$ 89.5</b>	<b>\$ 129.5</b>
Income from equity method investments	\$ (0.8)	\$ (0.8)
Other, net	3.3	3.3
Stock-based compensation	16.0	16.0
APC excluded assets costs	12.0	12.0
<b>Adjusted EBITDA<sup>(1)</sup></b>	<b>\$ 120.0</b>	<b>\$ 160.0</b>

(1) See "Use of Non-GAAP Financial Measures" slide for more information.

# Summary of Selected Financial Results – Breaking Out Excluded Assets

	Three Months Ended March 31, 2023			Three Months Ended March 31, 2022		
<i>\$ in millions</i>	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets
<b>Revenue</b>						
Capitation, net	\$ 300.2	-	300.2	\$ 222.1	-	222.1
Risk pool settlements and incentives	13.5	-	13.5	18.1	-	18.1
Management fee income	9.9	-	9.9	10.5	-	10.5
Fee-for-service, net	12.1	-	12.1	11.1	-	11.1
Other income	1.6	-	1.6	1.6	-	1.6
<b>Total revenue</b>	<b>337.2</b>	<b>-</b>	<b>337.2</b>	<b>263.3</b>	<b>-</b>	<b>263.3</b>
Total operating expenses	314.9	0.9	314.0	237.0	0.6	236.4
<b>Income (loss) from operations</b>	<b>22.4</b>	<b>(0.9)</b>	<b>23.3</b>	<b>26.2</b>	<b>(0.6)</b>	<b>26.8</b>
Total other (expense) income, net	(3.0)	(0.8)	(2.2)	(7.9)	(7.5)	(0.4)
<b>Net income (loss)</b>	<b>\$ 14.3</b>	<b>(1.7)</b>	<b>16.0</b>	<b>\$ 12.1</b>	<b>(8.1)</b>	<b>20.2</b>



# Summary Balance Sheet – Breaking Out Excluded Assets

	March 31, 2023			December 31, 2022		
<i>\$ in millions</i>	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets
<b>Current assets</b>						
Cash and cash equivalents	\$ 274.6	16.1	258.5	\$ 288.0	30.2	257.8
Investments in marketable securities	4.1	1.5	2.6	5.6	4.5	1.1
Receivables, net	79.0	-	79.0	52.6	-	52.6
Receivables - related parties and loan receivable - related party	74.9	-	74.9	67.2	-	67.2
Other receivables, prepaid expenses and other current assets, and loans receivable	25.1	10.0	15.1	17.6	0.8	16.8
Income taxes receivable	-	-	-	4.0	(1.1)	5.1
Total current assets	457.7	27.6	430.1	435.0	34.4	400.6
<b>Non-current assets</b>						
Land, property, and equipment, net	113.4	106.3	7.1	108.5	101.3	7.2
Goodwill and intangibles	353.7	-	353.7	352.6	-	352.6
Loan receivable and loan receivable - related parties, net of current	-	-	-	-	-	-
Investments in other entities and privately held entities	44.0	29.8	14.2	41.2	27.6	13.6
Other assets and right-of-use assets	23.8	2.5	21.3	26.5	3.2	23.3
Total non-current assets	534.9	138.6	396.3	528.8	132.1	396.7
<b>Total assets</b>	<b>\$ 992.6</b>	<b>166.2</b>	<b>826.4</b>	<b>\$ 963.8</b>	<b>166.5</b>	<b>797.3</b>

# Summary Balance Sheet – Breaking Out Excluded Assets (continued)

\$ in millions	March 31, 2023			December 31, 2022		
	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets
<b>Current liabilities</b>						
Fiduciary payable, accounts payable and accrued liabilities	\$ 58.5	1.3	57.2	\$ 57.7	2.8	54.9
Medical liabilities	101.4	-	101.4	84.3	-	84.3
Income taxes payable	-	1.1	(1.1)	-	-	-
Dividend payable	0.7	-	0.7	0.7	-	0.7
Finance and operating lease liabilities	3.8	-	3.8	4.2	-	4.2
Current portion of long-term debt	0.6	0.6	-	0.6	0.6	-
Total current liabilities	165.0	3.0	162.0	147.5	3.4	144.1
<b>Non-current liabilities</b>						
Deferred tax liability	3.7	0.9	2.8	3.0	0.9	2.1
Finance and operating lease liabilities, net of current portion	19.3	-	19.3	21.2	-	21.2
Other long-term liabilities	21.8	-	21.8	20.3	-	20.3
Long-term debt, net of current portion and deferred financing costs	204.9	28.0	176.9	203.4	26.6	176.8
Total non-current liabilities	249.7	28.9	220.8	247.9	27.5	220.4
<b>Total liabilities</b>	<b>414.7</b>	<b>31.9</b>	<b>382.8</b>	<b>395.4</b>	<b>30.9</b>	<b>364.5</b>
<b>Total mezzanine equity and stockholder's equity</b>	<b>\$ 577.9</b>	<b>134.3</b>	<b>433.6</b>	<b>\$ 568.4</b>	<b>135.6</b>	<b>432.8</b>

# Summary Cash Flow Statement – Breaking Out Excluded Assets

\$ in millions	March 31, 2023			March 31, 2022		
	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets
<b>Cash flows from operating activities</b>						
Net income	\$ 14.3	(1.8)	16.1	\$ 12.1	(8.1)	20.2
Adjustments to reconcile net income to net cash provided by operating activities:						
Depreciation and amortization	\$ 4.3	0.4	3.9	\$ 4.4	0.2	4.2
Amortization of debt issuance cost	0.2	-	0.2	0.2	-	0.2
Share-based compensation	3.4	-	3.4	3.1	-	3.1
Gain on sale of investments <sup>2</sup>	-	-	-	-	-	-
Unrealized loss on investments <sup>2</sup>	5.8	3.0	2.8	10.6	10.6	-
Income from equity method investments, net <sup>2</sup>	(2.5)	(2.2)	(0.3)	(1.4)	(1.3)	(0.1)
Unrealized gain on interest rate swaps <sup>2</sup>	0.6	0.6	-	(1.6)	(1.6)	-
Deferred tax <sup>2</sup>	0.8	-	0.8	2.0	-	2.0
Changes in operating assets and liabilities, net of acquisition amounts: <sup>2</sup>						
Receivables, net, receivable, net - related parties, other receivable, prepaid expenses and other current assets, right of use assets, other assets, fiduciary accounts payable, medical liabilities, and operating lease liabilities	(18.8)	(0.4)	(18.4)	(13.1)	0.8	(13.9)
Accounts payable and accrued liabilities	(4.4)	(1.5)	(2.9)	3.7	-	3.7
Income taxes payable <sup>2</sup>	4.0	-	4.0	4.2	-	4.2
Net cash provided by (used in) operating activities <sup>2</sup>	\$ 7.7	(1.9)	9.6	\$ 24.0	0.6	23.4

# Summary Cash Flow Statement – Breaking Out Excluded Assets (continued)

\$ in millions	March 31, 2023			March 31, 2022		
	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets	ApolloMed Consolidated	Excluded Assets	ApolloMed Assets
<b>Cash flows from investing activities</b>						
Payments for business acquisition, net of cash acquired	\$ -	-	-	\$ (1.0)	-	(1.0)
Proceeds from repayment of loans receivable - related parties	2.1	-	2.1	-	-	-
Purchase of marketable securities	(1.0)	-	(1.0)	\$ -	-	-
Purchase of investments - equity method	(0.3)	-	(0.3)	-	-	-
Purchases of property and equipment	(6.0)	(5.3)	(0.7)	(17.5)	(17.5)	-
Deposit for purchase of property	(8.8)	(8.8)	-	-	-	-
Distribution from investments - equity method	-	-	-	0.2	-	0.2
Contribution to investment - equity method	-	-	-	(1.4)	(1.4)	-
Net cash (used in) provided by investing activities	(14.0)	(14.1)	0.1	(19.7)	(19.0)	(0.7)
<b>Cash flows from financing activities</b>						
Dividends paid	\$ (0.1)	-	(0.1)	\$ (1.2)	-	(1.2)
Repayments on long-term debt	(0.2)	(0.2)	-	(0.1)	0.7	(0.8)
Payment of finance lease obligations	(0.2)	-	(0.2)	(0.1)	-	(0.1)
Proceeds from exercise of stock options and warrants	1.3	-	1.3	1.6	-	1.6
Repurchase of treasury shares	(9.5)	-	(9.5)	(0.2)	-	(0.2)
Purchase of non-controlling interest	-	-	-	(0.2)	-	(0.2)
Proceeds from sale of non-controlling interest	-	-	-	-	-	-
Borrowings on loans	1.6	1.5	0.1	0.7	-	0.7
Amounts due from affiliates	-	0.6	(0.6)	-	(19.2)	19.2
Net cash (used in) provided by financing activities	\$ (7.1)	1.9	(9.0)	\$ 0.5	(18.5)	19.0
Net change in cash and cash equivalents	(13.4)	(14.1)	0.7	4.8	(36.9)	41.7
Cash and cash equivalents at beginning of year	\$ 288.0	30.2	257.8	\$ 233.1	62.6	170.5
Cash and cash equivalents at end of year	\$ 274.6	16.1	258.5	\$ 237.9	25.7	212.2



# Use of Non-GAAP Financial Measures

This presentation contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.



**For inquiries, please contact:**

ApolloMed Investor Relations  
(626) 943-6491  
[investors@apollomed.net](mailto:investors@apollomed.net)

Carolyne Sohn, The Equity Group  
(408) 538-4577  
[csohn@equityny.com](mailto:csohn@equityny.com)





